DDrare: Database of Drug Development for Rare Diseases

Molgramostim nebulizer solution (DrugBank: Molgramostim)

2 diseases

ID	Disease name (Link within this page)	Number of trials
229	Autoimmune pulmonary alveolar proteinosis	1
299	Cystic fibrosis	1

229. Autoimmune pulmonary alveolar proteinosis [ 35 clinical trials, 30 drugs, (DrugBank: 8 drugs), 3 drug target genes, 12 drug target pathways]

Searched query = "Autoimmune pulmonary alveolar proteinosis", "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 35 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04544293 (ClinicalTrials.gov)	February 2021	3/9/2020	Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Autoimmune Pulmonary Alveolar Proteinosis	Drug: Molgramostim;Drug: Placebo	Savara Inc.	NULL	Not yet recruiting	18 Years	N/A	All	160	Phase 3	NULL

299. Cystic fibrosis [ 1,592 clinical trials, 1,539 drugs, (DrugBank: 255 drugs), 81 drug target genes, 162 drug target pathways]

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 1,592 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03597347 (ClinicalTrials.gov)	June 20, 2019	12/7/2018	Trial of Inhaled Molgramostim in CF Subjects With NTM Infection	An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection	Mycobacterium Infections, Nontuberculous;Cystic Fibrosis (CF)	Drug: Molgramostim nebulizer solution;Device: PARI eFlow nebulizer system	Savara Inc.	NULL	Active, not recruiting	18 Years	N/A	All	30	Phase 2	United States